PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009

... generation recombinant protective antigen (rPA) anthrax vaccine Third generation rPA anthrax vaccine Valortim((R)) -- a fully human ... antibody for the prevention and treatment of anthrax infection Protexia((R)) -- a novel ...

Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia

... survival rate against an inhaled lethal dose of anthrax following a 14-day course of treatment in a ... for the prophylactic treatment of inhalation anthrax post-exposure. The FDA has designated Restanza as ... drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved ...

PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants

... generation recombinant protective antigen (rPA) anthrax vaccine Third generation rPA anthrax vaccine Valortim(R) - a fully ... antibody for the prevention and treatment of anthrax infection Protexia(R) - a novel ...

Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government

... to see a large-scale version of the inhalation anthrax attacks that took place in 2001, but HGS is proud ... the U.S. Government. "It is widely known that anthrax spores can be aerosolized and turned into a ... Raxibacumab represents a new way to address the anthrax threat. While antibiotics can kill ...

PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review

... generation recombinant protective antigen (rPA) anthrax vaccine. In response to amendments to the ... second generation recombinant protective (rPA) anthrax vaccine being developed for administration by ... against a lethal aerosol spore challenge of the anthrax Ames strain. The clinical and non-clinical ...

Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax

... in the event of life-threatening inhalation anthrax disease. (Logo: ... highly effective as a treatment for inhalation anthrax in both rabbits and monkeys," said Sally D. ... caused by exposure to a dose of aerosolized anthrax spores that was approximately 200 times the ...

Novel handheld device detects anthrax with outstanding accuracy and reliability

... detection device in discriminating between anthrax spores and similar-looking hoax substances. The ... Ceeker scanner accurately identified 100% of the anthrax samples used and was correct in 95% of tests ... outstanding results in distinguishing between anthrax and look-alike hoax substances, and now we have ...

Independent U.S. Study Confirms Veritide's Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability

... Research Institute, Ceeker Correctly Detected anthrax 100% of the Time-- --Provides First ... detection device in discriminating between anthrax spores and similar-looking hoax substances. The ... Ceeker scanner accurately identified 100% of the anthrax samples used and was correct in 95% of tests ...

Advanced Life Sciences' Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study

... mg) of Restanza within 24 hours after exposure to anthrax survived while none of the animals that received ... prophylactic treatment of inhalation anthrax indication. We are looking forward to working ... prophylactic treatment of inhalation anthrax to help protect against human infection from ...

PharmAthene Reports First Quarter 2009 Financial and Operational Results

... RypVax(TM) and our third generation rPA anthrax vaccine programs, which we acquired in the second ... generation recombinant protective antigen (rPA) anthrax vaccine Third generation rPA anthrax vaccine Valortim(R) - a fully human ...

PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research

... compared our vaccine to the currently licensed anthrax vaccine, BioThrax(R), provides further ... generation recombinant protective antigen (rPA) anthrax vaccine that is being developed for pre and post exposure protection against anthrax infection. SparVax(TM) Phase II Clinical ...

ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canada's Ability to Deal with Biological Threats

... of IVT's DepoVax(TM) vaccine formulation to anthrax antigens to explore new methods to prevent, ... of an effective anti-anthrax vaccine." anthrax is an acute infectious disease caused by the ... bacterium Bacillus anthracis. Infection with anthrax is very serious, and potentially life ....

New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague

... Identification Technology allows the viewing of anthrax cultures four times faster than conventional ... BNP(TM) technology displayed colonies of anthrax in six hours, as contrasted with the fastest ... essential." The bacteria responsible for anthrax and Bubonic plague are category A select agents, ...

PharmAthene Announces $5.5 Million Public Equity Offering

... generation recombinant protective antigen (rPA) anthrax vaccine Third generation rPA anthrax vaccine Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection Protexia(R) - a novel ...

PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009

... generation recombinant protective antigen (rPA) anthrax vaccine Third generation rPA anthrax vaccine Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection Protexia(R) - a novel ...

PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting

... generation recombinant protective antigen (rPA) anthrax vaccine that is being developed for pre and post exposure protection against anthrax infection. Valortim(R), in co-development with ... may be a promising second generation rPA anthrax vaccine candidate for civilian defense ...

Pharmathene Reports Third Quarter 2008 Financial and Operational Results

... contracts supporting the development of the rPA anthrax vaccines and RypVax(TM) plague vaccine product ... recombinant protective antigen (rPA) anthrax vaccine -- Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia(R) - a novel bioscavenger ...

PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008

... recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine -- Valortim(R) -- a fully human ... antibody for the prevention and treatment of anthrax infection -- Protexia(R) -- a novel bioscavenger ...

PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference

... recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine -- Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia(R) - a novel bioscavenger ...

Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)

... from a pilot study showing that the anthrax anti-toxin, Valortim(R) (MDX-1303), enhanced ... a prophylactic and therapeutic for inhalation anthrax infection. Based on these results, we believe ... refine this model for therapeutic intervention in anthrax infection, further defining the potential ...

PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases

... recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine -- Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia(R) - a novel bioscavenger ...

PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program

... generation recombinant protective antigen (rPA) anthrax vaccine. The objective of the government's third generation program is to develop an rPA anthrax vaccine which can be stored, transported and ... continued development of our third generation rPA anthrax vaccine program. This latest contract is in ...

PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008

... recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine -- Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia(R) - a novel bioscavenger ...

PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008

... recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine -- Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia(R) - a novel bioscavenger ...

PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration

... for its recombinant protective antigen anthrax vaccine, SparVax(TM), has completed a ... was in response to a Request for Proposals for an anthrax Recombinant Protective Antigen (rPA) Vaccine for ... to develop and procure 25 million doses of an anthrax rPA vaccine. "We are delighted by this news and ...

PharmAthene Reports Second Quarter 2008 Financial and Operational Results

... generation recombinant protective antigen (rPA) anthrax vaccine for inclusion in the Strategic National ... development funding for a third generation rPA anthrax vaccine; and next month we expect to begin ... for procurement award for second generation rPA anthrax vaccine by year end -- Decision anticipated ...

Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene

... generation recombinant protective antigen (rPA) anthrax vaccine -- Valortim(R) -- a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia(R) -- a novel ... antigen vaccine for plague a third generation rPA anthrax vaccine. For more information about ...

PharmAthene Reports First Quarter 2008 Financial Results

... novel, next generation rPA anthrax vaccines, an anthrax anti-toxin, Valortim(TM), a chemical nerve agent ... of PharmAthene's second generation rPA anthrax vaccine. The RFP has a requirement to procure 25 million doses of rPA anthrax vaccine. -- File an Investigational New Drug ...

Elusys' Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection

... Elusys' Anthim is designed as a "just in time" anthrax therapeutic that can be administered by a single, ... infected with a highly lethal dose of aerosolized anthrax spores and observed for 60 days. A single IM dose ... 100 percent protection when given prior to an anthrax exposure. These results have been consistent ...

PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit

... -- A recombinant Protective Antigen (rPA) anthrax vaccine -- A recombinant dual antigen Plague ... manufactured in E coli -- A third generation rPA anthrax vaccine program -- Valortim(TM), a fully human ... Medarex for the prevention and treatment of anthrax infection -- Protexia(R) a novel bioscavenger to ...

Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process

... Phase II Phase III (2009) anthrax Preclinical Phase I (2008) ... Nordic has initiated a preclinical program for an anthrax vaccine. The Company sees a number of synergies - ... against two of the top biological threats. The anthrax program is expected to enter Phase I in 2008. ...

PharmAthene Reports Year-End 2007 Financial Results

... therapeutic to prevent and treat inhalational anthrax infection. -- Obtaining up to an additional ... a new primate model of established inhalation anthrax infection -- the African Green Monkey model, ... including a recombinant Protective Antigen (rPA) anthrax vaccine, a novel dual antigen plague vaccine, ...

PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia

... plague vaccine, and a third generation rPA anthrax vaccine program. As part of this ... upon receipt of procurement contracts for the anthrax rPA vaccines and the plague vaccine, and ... -- a recombinant Protective Antigen (rPA) anthrax vaccine -- Valortim(TM), a fully human ...

Taming the anthrax threat

... the potential for terrorists to cause a deadly anthrax outbreak remains a significant concern, six years ... attackers during the crucial first moments of anthrax infection. They have also identified gene candidates to pursue as possible anthrax drug targets. They say the methods they used to ...

Anthrax vaccine produces immunity with nanoparticles, not needles

... ANN ARBOR, Mich. A vaccine against anthrax that is more effective and easier to administer ... The oil particles are small enough to ferry a key anthrax protein inside the nasal membranes, allowing ... the need for needles, the nanoemulsion anthrax vaccine has another advantage, the researchers ...

Taming the anthrax threat

... the potential for terrorists to cause a deadly anthrax outbreak remains a significant concern, six years ... attackers during the crucial first moments of anthrax infection. They have also identified gene candidates to pursue as possible anthrax drug targets. They say the methods they used to ...

Anthrax vaccine produces immunity with nanoparticles, not needles

... ANN ARBOR, Mich. A vaccine against anthrax that is more effective and easier to administer ... The oil particles are small enough to ferry a key anthrax protein inside the nasal membranes, allowing ... the need for needles, the nanoemulsion anthrax vaccine has another advantage, the researchers ...

NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection

... explore the potential of rapid determination of anthrax spore viability, utilizing NanoLogix's ... to determine the viability and persistence of anthrax spores much faster than current methods due to ... has been made in our research efforts simulating anthrax spore growth through the use of ...

Novel method predicts impact of a covert anthrax release

... Previously published methods can estimate the date and scale of anthrax release but not the source location or geographic extent of human ... and the people and geographic areas likely to be worst affected." anthrax has the potential to cause a large number of deaths in the event of a ...

Novel method predicts impact of a covert anthrax release

... Previously published methods can estimate the date and scale of anthrax release but not the source location or geographic extent of human ... and the people and geographic areas likely to be worst affected." anthrax has the potential to cause a large number of deaths in the event of a ...